S1PR3
Sphingosine 1-phosphate receptor 3
As of the edition of 20 October 2026, S1PR3 (sphingosine 1-phosphate receptor 3, UniProt Q99500) has 2 drugs tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q99500
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 9
- Disease areas
- Nervous system; Immune system; Heart and blood vessels; Digestive system; Cancer; Skin and connective tissue; Lungs and airways; Nutrition and metabolism
- Registered trials of its drugs
- 97
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fingolimod | Marketed | Phase 4 | none listed |
| Amiselimod | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Mitsubishi Tanabe Pharma | Route B |
The other 3 companies at S1PR3
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at S1PR3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.